Eribulin in HER2 Negative Metastatic BrCa

Inclusion Criteria:

Histologically or cytologically proven invasive breast cancer, locally recurrent or metastatic, with at least one measureable lesion according to RECIST v1.1
Hormone receptor positive or hormone receptor negative HER2-negative disease
Up to one prior line of chemotherapy for advanced disease is allowed (discontinued at least 14 days prior to initiation of protocol therapy)
Prior bevacizumab in the neo/adjuvant or metastatic setting is acceptable
No limit on prior lines of endocrine therapy, but must be discontinued at least 7 days prior to initiation of protocol therapy
Must have completed any prior radiotherapy at least 2 weeks prior to initiation of protocol therapy
Must have recovered from reversible effects of prior therapies to no more than grade 1 toxicity, with the exception of alopecia
Agree to use adequate contraception for the duration of study participation

Exclusion Criteria:

Pregnant or breastfeeding
Prior treatment with eribulin
Prior malignancy other than carcinoma in situ of the cervix or nonmelanoma skin cancer unless diagnosed and definitively treated at least 3 years before enrollment in this study
Clinically significant cardiovascular impairment
Active brain metastases or unevaluated neurologic symptoms suggestive of brain metastases
Pulmonary dysfunction requiring the use of oxygen
Prior organ allograft requiring immunosuppression
HIV positive on combination antiretroviral therapy
Pre-existing grade 3 or 4 neuropathy
Hypersensitivity to halichondrin B or halichondrin B chemical derivative
Uncontrolled intercurrent illness
Inability to read in English